FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease
German Cancer Research Center · Heidelberg University · +3 more institutions
Abstract
Gallium 68 (68Ga)–labeled fibroblast activation protein (FAP) inhibitor (FAPI) PET is based on the molecular targeting of the FAP, which is known to be highly expressed in the major cell population in tumor stroma, termed cancer-associated fibroblasts. Among many FAP-targeted radiopharmaceuticals developed so far, 68Ga-FAPI exhibits rapid tracer accumulation in target lesions and low background signal, which results in excellent imaging features. FAPI PET can be integrated in the clinical workflow and enables the detection of small primary or metastatic lesions, especially in the brain, liver, pancreas, and gastrointestinal tract due to the low tracer accumulation in these organs. Moreover, the DOTA…
Citation impact
- FWCI
- 70.22
- Percentile
- 100%
- References
- 59
Authors
6- YMYuriko MoriCorresponding
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
- KDKatharina Dendl
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
- JCJens Cardinale
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
- CKClemens Kratochwil
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
- FLFrederik L. Giesel
German Cancer Research Center, Heidelberg University, University Hospital Heidelberg, Düsseldorf University Hospital, Heinrich Heine University Düsseldorf
Topics & keywords
- Fibroblast activation protein, alpha
- Medicine
- DOTA
- Cancer research
- Molecular imaging
- Population
- Cancer
- Stroma
- Good health and well-being